Pediatric Invasive Group A Streptococcal Disease: Early Recognition, Rapid Deterioration, and Emergency Department Management

Abstract Purpose of Review Invasive group A streptococcal infections (iGAS) are uncommon but life-threatening conditions in children. Following the COVID-19 pandemic, several countries have reported a resurgence of pediatric iGAS cases with increased disease severity and higher rates of intensive care admission. This narrative review provides a practical clinical overview for emergency physicians on the early recognition, diagnostic approach, and management of pediatric iGAS in the post-COVID era. It synthesizes current epidemiological studies, clinical evidence, and guideline recommendations on pediatric iGAS, with emphasis on early warning signs, diagnostic strategies, and time-critical emergency department management. Recent Findings Recent epidemiologic data demonstrate a marked rise in pediatric iGAS incidence since 2022. Key risk factors include age under five years, viral respiratory coinfections (particularly influenza and respiratory syncytial virus), varicella infection, and the circulation of virulent emm serotypes. Clinical presentations range from bacteremia and pneumonia to severe toxin-mediated syndromes such as streptococcal toxic shock syndrome and necrotizing fasciitis. Early warning signs include rapid clinical deterioration, severe pain out of proportion to examination findings, gastrointestinal symptoms, altered mental status, and hemodynamic instability. Prompt diagnostic evaluation, including laboratory testing, microbiologic cultures, and targeted imaging, is essential. Emergency management requires rapid sepsis resuscitation, early combination antibiotic therapy (for sepsis, empirical β-lactam therapy; for suspected iGAS, empirical antibiotic therapy should provide coverage for both Staphylococcus aureus and iGAS using a β-lactam plus clindamycin for its antitoxin effects; for confirmed iGAS caused by β-lactam-susceptible iGAS, treatment should be β-lactam therapy plus clindamycin and vancomycin. Following empirical treatment, antibiotic regimens should be tailored according to culture results and the clinical presentation), and urgent surgical consultation when necrotizing infection is suspected. Adjunctive therapies such as intravenous immunoglobulin may be considered in toxin-mediated disease. Summary The post-pandemic resurgence of pediatric iGAS highlights the need for heightened clinical vigilance in emergency settings. Early recognition of red flags, and rapid initiation of appropriate management are critical to reducing morbidity and mortality in affected children.